Antibodies against human NKG2D and uses thereof

US10526409B2 · kind B2 · utility

Assignee

• Novo Nordisk A/S · DK

Inventors

• Birgitte Urso · Copenhagen, DK
• Peter Andreas Nicolai Reumert Wagtmann · Hørsholm, DK
• Inger Lund Pedersen · Copenhagen, DK
• Anders Svensson · Malmö, SE

Key dates

• Filing date: Sep 18, 2017
• Grant date: Jan 7, 2020
• Expiry date: Sep 18, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies.